Medline ® Abstract for Reference 14
of 'Treatment of relapsed or refractory acute myeloid leukemia'
Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse.
Giles F, Verstovsek S, Garcia-Manero G, Thomas D, Ravandi F, Wierda W, Ferrajoli A, Kornblau S, Jabbour E, Shan J, O'brien S, Albitar M, Kantarjian H
Br J Haematol. 2006;134(1):58.
In order to validate the European Prognostic Index (EPI) for patients<or=60 years with acute myeloid leukaemia in first relapse, a cohort of 599 such patients, treated between 1980 and 2004 at the MD Anderson Cancer Center, were assessed using this prognostic index. Three risk groups were defined: favourable, 76 patients (13%) [Overall survival (OS), 64% at 1 year, 22% at 5 years]; intermediate, 137 patients (23%) (OS, 38% at 1 year, 12% at 5 years); and poor, 386 patients (64%) (OS, 17% at 1 year 6% at 5 years). The EPI is reproducible and useful.
Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, 77230-1402, USA. firstname.lastname@example.org